– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline ...
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty...
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty...
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)...
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...
– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity...
– Continued advancement across diversified development pipeline – Company ended the quarter with $63.6 million in cash, expected to fund operations...
– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease ("PD"), a...
– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue...